[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100570893":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":30,"responsibleParty":52,"collaborators":54,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":10,"studyType":70,"phases":10,"briefSummary":71,"conditions":72,"keywords":77,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Yunnan Cancer Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"NIR-II probe incubation",null,"The fresh excision breast tissues or SLN will be completely soaked in the NIR-II probe (i.e:ICG-POL6326) incubation solution (12.5,25,50,100 ug\u002FmL) for1, 3, 5,7 or 10 min, followed by 5 min of rinsing with PBST buffer and drying with absorbent paper.The NIR-II fluorescence imaging will be then performed under the DPM NIR-II system. And the correlation between pathological characterization and fluorescent information will be further analyzed.",[13],"Diagnostic Test: NIR-II Probe(i.e ICG-POL6326) incubation solution",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DIAGNOSTIC_TEST","NIR-II Probe(i.e ICG-POL6326) incubation solution","After the tissues were incubated with the optimal concentration of the NIR-II probe for the appropriate time, the tissues were washed with the eluate, and then the fluorescence intensity of different tissues was detected to evaluate whether the tissues had cancer tissue invasion.",[9],[21,26],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Yuanyuan Zhu,Doctor","CONTACT","86+18059766094","18059766094@163.com",{"name":27,"role":23,"phone":28,"phoneExt":10,"email":29},"Weiling Chen, Doctor","86+13646039812","913208146@qq.com",[31],{"facility":5,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"RECRUITING","Kunming","Yunnan","650118","China","CN",{"type":39,"coordinates":40},"Point",[41,42],102.71833,25.03889,{"lat":42,"lon":41},[45,46,48,50,51],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},{"name":47,"role":23,"phone":28,"phoneExt":10,"email":29},"Weiling Chen,Doctor",{"name":49,"role":23,"phone":10,"phoneExt":10,"email":10},"Guojun Zhang, Doctor",{"name":22,"role":23,"phone":10,"phoneExt":10,"email":10},{"name":47,"role":23,"phone":10,"phoneExt":10,"email":10},{"type":53,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[55],{"name":56,"class":6},"Xiang'an Hospital of Xiamen University","100570893","tumor-targeted-nir-ii-fluorescent-molecular-probes-for-the-identification-of-breast-cancer-tissue-and-sln-metastatic-status-100570893",false,"NCT06713161","Tumor-Targeted-NIR-II Fluorescent Molecular Probes for the Identification of Breast Cancer Tissue and SLN Metastatic Status","NIR-II","Inclusion Criteria:\n\n* Adult patients between 18-75 years of age\n* Female\n* Patients presenting with a breast nodule or mass presumed to be resectable on pre-operative assessment\n* Good operative candidate\n* Subject capable of giving informed consent and participating in the process of consent\n\nExclusion Criteria:\n\n* Patients unable to participate in the consent process\n* Patients had contraindications to surgery, such as serious cardiopulmonary disease, coagulation dysfunction, etc\n* Other conditions that the researcher considers inappropriate to participate in the study","FEMALE","18 Years","75 Years",{"count":68,"type":69},40,"ESTIMATED","OBSERVATIONAL","Accurate evaluation of tumor boundaries in breast-conserving surgery is closely associated with reducing the second operation of patients. Meanwhile, accurately assessing sentinel lymph node (SLN) metastasis is crucial for determining the extent of axillary lymph node dissection (ALND) and minimizing complications. Near-infrared-II (NIR-II) fluorescence imaging using molecular agents has shown promise for in situ imaging during resection. However, very effective probes can be applied to clinical trials up to now, which limits the clinical application of fluorescence imaging. Here we developed a new technology that can quickly differentiation between cancer and para-cancer tissue as well as metastatic and normal sentinel lymph nodes(SLN). In brief, the fresh tissues were incubated with the probe immediately after intraoperative resection and imaged to identify the tumor area and distinguish the metastatic status of SLN. The accuracy of fluorescence imaging was confirmed by pathological diagnosis.",[73,74,75,76],"Breast Cancer","Sentinel Lymph Node","Metastases","Margin Assessment",[62,73,74,78,75],"Surgical Navigation","2024-11-27",{"date":81,"type":82},"2024-12-03","ACTUAL",{"date":84,"type":82},"2024-09-01",{"date":86,"type":69},"2025-12-25",{"name":5,"class":6},1]